Compare iShares MSCI Taiwan ETF (EWT) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Taiwan ETF vs Sana Biotechnology Inc — how do they compare? iShares MSCI Taiwan ETF trades at $114.31 (market cap $12.74B), while Sana Biotechnology Inc trades at $2.79 (market cap $836.71M). The key difference: iShares MSCI Taiwan ETF is far larger — about 15.2× Sana Biotechnology Inc's market cap, and iShares MSCI Taiwan ETF is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Taiwan ETF for 52 Days and Sana Biotechnology Inc for 23 Days on average.
| EWT | SANA | |
|---|---|---|
Market Cap | $12.74B | $836.71M |
Volume | 8,470,920 | 4,507,444 |
Sector | Broad Market / Factor | Health |
52-Week High | $118.00 | $5.92 |
52-Week Low | $60.03 | $2.68 |
Typical Hold Time | 52 Days | 23 Days |
Enterprise Value | — | $749.96M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWT (iShares MSCI Taiwan ETF) trades at $113.34, down 2.49% on the day, with a bullish technical signal from moving averages despite neutral oscillators. The ETF remains heavily concentrated in Taiwan's semiconductor sector, particularly TSMC, benefiting from strong AI-driven demand. Recent news highlights Taiwan's $20 billion investment in US AI infrastructure and continued institutional interest, though geopolitical tensions with China present ongoing risks.
The outlook for EWT is positive due to Taiwan's critical role in AI semiconductor supply chains and reasonable tech valuations. Key opportunities include sustained AI demand and corporate investments, while risks center on China-Taiwan geopolitical friction and semiconductor cycle volatility. Wall Street maintains a bullish stance given growth-adjusted valuation metrics.
SANA Biotechnology trades at $2.79, up 2.57% today, but faces significant fundamental challenges with negative revenue, substantial losses, and bearish technical indicators. The company reported a net loss of $244.17 million in 2025 with no revenue, while technical analysis shows a bearish trend with moving averages and ADX indicators signaling selling pressure. Recent news highlights multiple investor conference presentations and ongoing legal scrutiny regarding fiduciary duties.
Despite strong analyst support (82% buy ratings), SANA's lack of revenue generation and negative profitability metrics present substantial investment risk. The company's cash flow remains negative, requiring continued financing. Near-term catalysts include upcoming Q3 earnings and clinical developments, but investors should weigh the high-risk profile against potential long-term biotechnology breakthroughs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares MSCI Taiwan ETF
EWT tracks the MSCI Taiwan 25/50 Index, providing targeted exposure to large and mid-cap companies in Taiwan. It is heavily concentrated in the information technology sector, serving as a liquid instrument for investors seeking a single-country view of Taiwan's export-oriented and tech-driven economy.
Read more on EWT →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
